[Federal Register Volume 71, Number 57 (Friday, March 24, 2006)]
[Notices]
[Page 14948]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-4302]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 13, 2005, Cerilliant API 
Services, LLC, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made 
application to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed in Schedule I and II; and by letter dated September 
2, 2005, to modify its name to Austin Pharma, LLC.

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinois (7370)...............  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Benzylmorphine (9052)......................  I
Codeine-N-oxide (9053).....................  I
Cyprenorphine (9054).......................  I
Desomorphine (9055)........................  I
Etorphine (9056)...........................  I
Codeine methylbromide (9070)...............  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Hydromorphinol (9301)......................  I
Methyldihydromorphine (9304)...............  I
Morphine methylbromide (9305)..............  I
Morphine-N-oxide (9307)....................  I
Alphamethadol (9605).......................  I
Normethadone (9635)........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Levomethorphan (9210)......................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Poppy Straw Concentrate (9670).............  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    In reference to drug code 7360 (Marihuana), the company plans to 
bulk manufacture cannabidiol as a synthetic intermediate. This 
controlled substance will be further synthesized to bulk manufacture a 
synthetic THC (7370). No other activity for this drug code is 
authorized for this registration.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than May 23, 2006.

    Dated: March 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-4302 Filed 3-23-06; 8:45 am]
BiLLiNG CODE 4410-09-P